Repligen (RGEN) Set to Announce Earnings on Tuesday

Repligen (NASDAQ:RGEN) is set to post its quarterly earnings results before the market opens on Tuesday, July 30th. Analysts expect Repligen to post earnings of $0.33 per share for the quarter. Repligen has set its FY24 guidance at $1.42-1.49 EPS and its FY 2024 guidance at 1.420-1.490 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. Repligen’s revenue was down 17.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.64 EPS. On average, analysts expect Repligen to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Price Performance

RGEN stock opened at $140.79 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The business has a 50 day simple moving average of $135.47 and a 200-day simple moving average of $166.50. The firm has a market capitalization of $7.87 billion, a PE ratio of 563.18, a price-to-earnings-growth ratio of 4.71 and a beta of 0.95. Repligen has a 1 year low of $110.45 and a 1 year high of $211.13.

Insider Buying and Selling

In other news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Martin D. Madaus purchased 1,615 shares of the stock in a transaction dated Friday, June 14th. The stock was acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the transaction, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on RGEN. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and dropped their price target for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Guggenheim began coverage on Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating for the company. Finally, JPMorgan Chase & Co. dropped their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $194.00.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.